All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On Sunday 17th June an oral abstract session took place at the 23rd Congress of the European Hematology Association (EHA). Abstract S1547 was presented by Yucai Wang, Mayo Clinic, Rochester, US, on the impact of concurrent follicular lymphoma (FL) or other low-grade lymphoma on the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). The study aimed to compare clinical characteristics and outcomes of patients with concurrent lymphoma or de novo DLBCL.
Dr Wang concluded that patients with DLBCL+FL at diagnosis mainly had Germinal center B-cell like (GCB) subtype, lower IPI scores and improved EFS and OS compared with de novo DLBCL patients. He added that DLBCL+FL is likely to behave similar to GCB DLBCL and that this should be taken into consideration when including these patients in DLBCL clinical trials.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox